Publication
A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.
Authors not recorded
BMC Cancer2012PMID 23181703PMC3515412stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerLung Acinar Adenocarcinomacivic_curation1.00
- drugErlotinibcivic_curation1.00
- geneALKcivic_curation1.00
- variantALK Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23181703
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ALK Fusion1 | ||||||||
| Erlotinib | Lung Acinar Adenocarcinoma | Predictive | C | Supports Resistance | 2 | accepted | EID1121A 39-year-old man presented was observed to have lung acinar adenocarcinoma. Treatment with chemotherapy produced no remarkable response. A EGFR L858R point mutation was observed; the patient was ther… (full text at CIViC) PMID 23181703 · Tanaka et al., 2012 · Open in CIViC | civic |